<DOC>
	<DOCNO>NCT00489541</DOCNO>
	<brief_summary>The purpose TAXUS PERSEUS Small Vessel trial evaluate safety efficacy next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system ( TAXUS® ElementTM ) treatment de novo atherosclerotic lesion 20 mm length native coronary artery ≥ 2.25 mm &lt; 2.75 mm diameter .</brief_summary>
	<brief_title>TAXUS PERSEUS Small Vessel</brief_title>
	<detailed_description>This prospective , multi-center , single-arm superiority trial ass TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System treatment de novo atherosclerotic lesion ≤20 mm length native coronary artery visual RVD ≥ 2.25 mm &lt; 2.75 mm diameter . Two hundred twenty-four ( 224 ) subject treat TAXUS Element stent maximum 35 clinical site . Follow-up 30 day , 9 month include angiography ) 1 year complete subject enrol study . Eligible subject annual follow-up 5 year post-index procedure .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Clinical Subject ≥ 18 year old Eligible percutaneous coronary intervention ( PCI ) Documented stable angina pectoris ( Canadian Cardiovascular Society [ CCS ] Classification 1 , 2 , 3 , 4 ) unstable angina pectoris ( Braunwald Class IBC , IIBC , IIIBC ) , document silent ischemia Acceptable candidate coronary artery bypass grafting ( CABG ) Left ventricular ejection fraction ( LVEF ) ≥ 30 % Subject ( legal guardian ) understand study requirement treatment procedure provide write Informed Consent studyspecific test procedure perform Subject willing comply specify followup evaluation Clinical Contraindication aspirin ( ASA ) , clopidogrel ticlopidine Known hypersensitivity paclitaxel Known allergy stainless steel Known allergy platinum Previous treatment target vessel antirestenotic drugcoated drugeluting coronary stent Previous treatment target vessel bare metal stent ( BMS ) within 9 month index procedure Previous treatment nontarget vessel antirestenotic drugcoated drugeluting coronary stent within 9 month index procedure Previous treatment intravascular brachytherapy target vessel Planned PCI CABG postindex procedure Planned actual target vessel treatment unapproved device , directional rotational coronary atherectomy , laser , cut balloon transluminal extraction catheter immediately prior stent placement Myocardial infarction ( MI ) within 72 hour prior index procedure Cerebrovascular accident ( CVA ) within past 6 month Cardiogenic shock Acute chronic renal dysfunction Prior anaphylactic reaction contrast agent Leukopenia Thrombocytopenia Thrombocytosis Active peptic ulcer active gastrointestinal ( GI ) bleed Current treatment , pasttreatment within 12months index procedure , paclitaxel chemotherapeutic agent Anticipated treatment paclitaxel oral rapamycin period 9months index procedure Known intention procreate within 9 month index procedure Positive pregnancy test within 7 day index procedure , lactate Life expectancy le 24 month due medical condition Comorbid condition ( ) could limit subject 's ability comply study followup requirement impact study scientific integrity Currently participate another investigational drug device study Angiographic Target Lesion Target lesion locate native coronary artery Target lesion must de novo Target lesion diameter stenosis ≥ 50 % Reference vessel diameter ( RVD ) ≥ 2.25 mm &lt; 2.75 mm Cumulative target lesion length ≤ 20 mm ( area treat may compose multiple lesion must completely coverable one study stent ) Target lesion successfully predilated One nontarget lesion may treat nontarget vessel follow : Nontarget lesion nontarget vessel must treat commercially available TAXUS stent use drug elute stent require Treatment must deem clinical angiographic success , without require use unplanned additional stent ( ) Treatment must complete prior treatment target vessel Angiographic Target lesion locate leave main artery , whether protect unprotected Target lesion chronic total occlusion ( TIMI flow ≤ 1 ) Target lesion restenotic Target lesion locate saphenous vein graft mammary artery graft Target lesion access via saphenous vein graft mammary artery graft Target lesion &lt; 5 mm bare metal stent ( BMS ) Target lesion &lt; 5 mm ostium Target lesion &lt; 5 mm side branch vessel ≥ 2.0 mm diameter ( Exceptions : subject may enrol side branch 100 % occluded side branch protect patent graft ) Untreated lesion ≥ 50 % diameter stenosis think impair flow remain target vessel location ≥ 2.0mm RVD Target lesion and/or target vessel proximal target lesion moderately severely calcified Target lesion and/or target vessel proximal target lesion severely tortuous Target lesion locate within distal &gt; 60° bend target vessel Target vessel angiographic presence probable definite thrombus Unprotected leave main coronary artery disease Protected leave main coronary artery disease target lesion Left Anterior Descending artery ( LAD ) Left Circumflex artery ( LCx ) . Subject may enrol lesion target lesion Right Coronary Artery ( RCA )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>paclitaxel-eluting stent</keyword>
	<keyword>PES</keyword>
</DOC>